- Conditions
- Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- Avacopan, Placebo, Standard of Care
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2036
- U.S. locations
- 62
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 245
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Asthma
- Interventions
- Procedure: Investigational Procedures
- Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 56
- States / cities
- Chandler, Arizona • Mesa, Arizona • Sun City, Arizona + 42 more
- Conditions
- Reverse Total Shoulder Arthroplasty, Rotator Cuff Tear Arthropathy, Advanced Glenohumeral Osteoarthritis
- Interventions
- Pectoralis Minor Release, RSA
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Vaginal Delivery, Pelvic Organ Prolapse
- Interventions
- Materna Prep Device
- Device
- Lead sponsor
- Materna Medical
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Mountain View, California + 11 more
- Conditions
- Hiv, HIV/AIDS, Disclosure
- Interventions
- Tough Talks Online, Tough Talks Clinic, Standard of Care
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 16 Years to 29 Years · Male only
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Prostate Cancer
- Interventions
- ASCENT
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 3 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF)
- Interventions
- Weight loss SOC Treatment with second generation anti-diabetic medications
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Lupus Nephritis
- Interventions
- secukinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
- Conditions
- Subdural Hematoma, Chronic
- Interventions
- SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation, Standard Medical Management
- Device · Procedure · Other
- Lead sponsor
- Balt USA
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Riverside, California + 21 more
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM
- Interventions
- SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide
- Device · Drug
- Lead sponsor
- CarThera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
- Drug · Radiation · Device
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Nasal Polyps
- Interventions
- Fevipiprant 150 mg, Fevipiprant 450 mg, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Hallux Valgus
- Interventions
- (EWB) Early Weight Bearing (2 Weeks Post-op)
- Other
- Lead sponsor
- Orthopaedic Associates of Michigan, PC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Acquired Immunodeficiency Syndrome, HIV
- Interventions
- Provider Visit Incentive (PVI), Incentive Choice (IC)
- Behavioral
- Lead sponsor
- National Bureau of Economic Research, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Interventions
- NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • St Louis, Missouri
- Conditions
- COVID-19
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more
- Conditions
- Gait
- Interventions
- standard of care treatment, Ankle Flexion Dynasplint
- Other · Device
- Lead sponsor
- Dynasplint Systems, Inc.
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Lubbock, Texas
- Conditions
- Pain, Postoperative, Lung Diseases
- Interventions
- Intercostal Nerve Cryoablation, Patient-controlled analgesia (PCA)
- Device · Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- AML, MDS
- Interventions
- SOC + TSC-101, Control, SOC + TSC-100
- Drug · Other
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 21
- States / cities
- Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more
- Conditions
- Burns, Trauma, Venous Ulcers
- Interventions
- MIST Therapy, Standard of care
- Device · Other
- Lead sponsor
- Celleration, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- Sexual Health Counseling, Enhanced Adherence Intervention, PrEP Information (Active Control), Standard of Care Adherence Support (Active Control)
- Behavioral
- Lead sponsor
- Hunter College of City University of New York
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 438 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
- Combination Product · Biological · Drug
- Lead sponsor
- Rakuten Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Duarte, California • Miami, Florida • Tampa, Florida + 5 more
- Conditions
- Tophaceous Gout
- Interventions
- Rituximab
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California